Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) is a biopharmaceutical company focused on developing and commercializing innovative therapies to improve patient lives. The company has shown significant growth, reporting record financial performance for the fourth quarter and full year of 2025. Xeris Biopharma is committed to strategic execution and has provided optimistic financial guidance for 2026.
On March 2, 2026, XERS reported earnings per share of $0.06, exceeding the estimated $0.03. This performance highlights the company's ability to surpass market expectations. Despite generating revenue of $85.8 million, which was slightly below the estimated $86 million, Xeris Biopharma's strategic focus remains evident.
The price-to-sales ratio of 3.48 shows that investors are willing to pay $3.48 for every dollar of sales, reflecting positive market sentiment. The company's enterprise value to sales ratio is 3.23, which reflects its total valuation compared to revenue. However, the enterprise value to operating cash flow ratio of 109.77 suggests that XERS is generating less cash flow relative to its valuation. This could be an area of concern for investors focusing on cash flow generation.
XERS has a debt-to-equity ratio of 2.76, indicating that the company has more than twice as much debt as equity. Despite this, the current ratio of 2.19 suggests that Xeris Biopharma has a strong ability to cover its short-term liabilities with its short-term assets, providing a cushion for financial stability.
